| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | epd |
| Uniprot No | P49419 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-539aa |
| 氨基酸序列 | AFMS TLLINQPQYA WLKELGLREE NEGVYNGSWG GRGEVITTYC PANNEPIARV RQASVADYEE TVKKAREAWK IWADIPAPKR GEIVRQIGDA LREKIQVLGS LVSLEMGKIL VEGVGEVQEY VDICDYAVGL SRMIGGPILP SERSGHALIE QWNPVGLVGI ITAFNFPVAV YGWNNAIAMI CGNVCLWKGA PTTSLISVAV TKIIAKVLED NKLPGAICSL TCGGADIGTA MAKDERVNLL SFTGSTQVGK QVGLMVQERF GRSLLELGGN NAIIAFEDAD LSLVVPSALF AAVGTAGQRC TTARRLFIHE SIHDEVVNRL KKAYAQIRVG NPWDPNVLYG PLHTKQAVSM FLGAVEEAKK EGGTVVYGGK VMDRPGNYVE PTIVTGLGHD ASIAHTETFA PILYVFKFKN EEEVFAWNNE VKQGLSSSIF TKDLGRIFRW LGPKGSDCGI VNVNIPTSGA EIGGAFGGEK HTGGGRESGS DAWKQYMRRS TCTINYSKDL PLAQGIKFQ |
| 预测分子量 | 58,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟示例文献(非真实存在，供参考格式)：
1. **《高效表达EPD重组蛋白的工程菌构建及发酵优化》**
作者：李明等
摘要：研究通过大肠杆菌表达系统构建EPD重组蛋白工程菌株，优化诱导条件使蛋白表达量提升3倍，为规模化生产奠定基础。
2. **《EPD重组蛋白的纯化工艺及其酶学特性分析》**
作者：Chen, X. & Wang, Y.
摘要：采用亲和层析法纯化EPD蛋白，纯度达95%，活性实验表明其最适pH为7.5.在生物催化领域具应用潜力。
3. **《基于EPD重组蛋白的肿瘤靶向药物递送系统研究》**
作者：Smith, J. et al.
摘要：开发了一种以EPD蛋白为载体的纳米颗粒，可特异性识别肿瘤细胞表面标记物，显著提升药物靶向性并降低小鼠模型毒副作用。
4. **《EPD重组蛋白在皮肤修复中的功能验证》**
作者：张璐等
摘要：体外实验证实EPD蛋白可促进成纤维细胞迁移与胶原合成，动物实验显示其加速创伤愈合，机制与激活MAPK通路相关。
---
**提示**：实际文献需通过PubMed、Web of Science等平台，以“EPD recombinant protein”、“EPD expression purification”等关键词检索。建议明确EPD的全称(如Epidermal Differentiation Protein)以精准查找。
**Background of EPD Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, are produced by inserting target DNA into host organisms (e.g., bacteria, yeast, or mammalian cells) to express specific proteins. EPD (Electrostatic Precipitation Device) recombinant proteins refer to a class of bioengineered proteins optimized for applications requiring high purity, stability, and controlled delivery, often leveraging electrostatic interactions for functional enhancement.
The development of EPD recombinant proteins stems from advances in recombinant DNA technology and protein engineering. These proteins are designed to address challenges in therapeutic delivery, diagnostics, and industrial biocatalysis. For instance, their electrostatic properties enable efficient binding to cell membranes or biomaterials, improving targeted drug delivery or biosensor performance.
In therapeutics, EPD recombinant proteins are explored for vaccines, cancer therapies, and regenerative medicine due to their ability to enhance immune responses or promote tissue repair. Their scalable production via microbial or cell culture systems aligns with cost-effective manufacturing needs. However, challenges remain in maintaining protein stability during electrostatic processing and ensuring biocompatibility.
Recent research focuses on optimizing expression systems, modifying surface charges via amino acid substitutions, and integrating nanotechnology for hybrid delivery platforms. As personalized medicine and biomanufacturing evolve, EPD recombinant proteins represent a versatile toolset bridging biotechnology and material science, with potential to revolutionize precision therapies and smart biomaterials.
×
